Jonathan M Tsai
Overview
Explore the profile of Jonathan M Tsai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
2509
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li Y, Ma M, Hassan M, Hunkeler M, Teng M, Puvar K, et al.
Nat Chem Biol
. 2024 Jul;
20(12):1640-1649.
PMID: 39075252
Molecular glues are proximity-inducing small molecules that have emerged as an attractive therapeutic approach. However, developing molecular glues remains challenging, requiring innovative mechanistic strategies to stabilize neoprotein interfaces and expedite...
2.
Tsai J, Nowak R, Ebert B, Fischer E
Nat Rev Mol Cell Biol
. 2024 Apr;
25(9):740-757.
PMID: 38684868
Targeted protein degradation refers to the use of small molecules to induce the selective degradation of proteins. In its most common form, this degradation is achieved through ligand-mediated neo-interactions between...
3.
Tsai J, Aguirre J, Li Y, Brown J, Focht V, Kater L, et al.
Mol Cell
. 2023 Jul;
83(15):2753-2767.e10.
PMID: 37478846
Nuclear hormone receptors (NRs) are ligand-binding transcription factors that are widely targeted therapeutically. Agonist binding triggers NR activation and subsequent degradation by unknown ligand-dependent ubiquitin ligase machinery. NR degradation is...
4.
Tsai H, Gogakos T, Lip V, Tsai J, Li Y, Fisch A, et al.
J Mol Diagn
. 2023 Jul;
25(9):665-681.
PMID: 37419244
Recognition of aberrant gene isoforms due to DNA events can impact risk stratification and molecular classification of hematolymphoid tumors. In myelodysplastic syndromes, KMT2A partial tandem duplication (PTD) was one of...
5.
Zou C, Yoon H, Park P, Patten J, Pellman J, Carreiro J, et al.
iScience
. 2023 Apr;
26(5):106601.
PMID: 37095859
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) hijacks multiple human proteins during infection and viral replication. To examine whether any viral proteins employ human E3 ubiquitin ligases, we evaluated the...
6.
Li Y, Ma M, Hassan M, Hunkeler M, Teng M, Puvar K, et al.
bioRxiv
. 2023 Feb;
PMID: 36824856
Small molecules that induce protein-protein interactions to exert proximity-driven pharmacology such as targeted protein degradation are a powerful class of therapeutics. Molecular glues are of particular interest given their favorable...
7.
Kim P, Niroula A, Shkolnik V, McConkey M, Lin A, Slabicki M, et al.
J Exp Med
. 2021 Oct;
218(12).
PMID: 34698806
Osteoporosis is caused by an imbalance of osteoclasts and osteoblasts, occurring in close proximity to hematopoietic cells in the bone marrow. Recurrent somatic mutations that lead to an expanded population...
8.
Tsai J, Hata A, Lennerz J
Oncologist
. 2021 Aug;
26(12):e2297-e2301.
PMID: 34347347
Comprehensive genetic profiling using next-generation sequencing technologies has become an integral part of precision oncology. Variant annotation requires translating the DNA findings into protein level predictions. In this article we...
9.
Tsai J, Tolan N, Petrides A, Kanjilal S, Brigl M, Lindeman N, et al.
J Appl Lab Med
. 2021 Apr;
6(5):1338-1354.
PMID: 33822967
The COVID-19 pandemic has made a devastating impact on global health and continues to challenge healthcare infrastructure and delivery. The clinical laboratories were no exception as they are responsible for...
10.
Slabicki M, Yoon H, Koeppel J, Nitsch L, Roy Burman S, Di Genua C, et al.
Nature
. 2020 Nov;
588(7836):164-168.
PMID: 33208943
Effective and sustained inhibition of non-enzymatic oncogenic driver proteins is a major pharmacological challenge. The clinical success of thalidomide analogues demonstrates the therapeutic efficacy of drug-induced degradation of transcription factors...